Uveal melanoma ranks as the most common type of intraocular tumor in adults globally, with its metastatic cancer holding a poor prognosis and a survival rate of around 10% at 2 years. Recent data reflects that at least 50% of the patients suffering from high-risk primary uveal melanoma are likely to develop a recurrence post-treatment of the primary tumor. Thus, due to the aggressive nature of this eye cancer and the availability of limited treatment options in advanced stages, there is an increased focus on the development of effective drugs to combat the disease.
The Uveal Melanoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into uveal melanoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for uveal melanoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveal melanoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveal melanoma.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveal melanoma.
Uveal melanoma (also known as choroidal melanoma) is the most commonly occurring primary intraocular malignancy in adults. In the United States, there were 3490 new cases of uveal melanoma in 2023. Although the incidence of this disease has remained nearly constant over the last few years, the main challenge of uveal melanoma lies in the metastatic stage, with survival rates of the patients dropping to only 16%.
The risk factors linked with uveal melanoma include increasing age and fair complexion. Chemotherapy and immunotherapy are common treatments for the disease. The first FDA-approved therapy for unresectable or metastatic uveal melanoma is Kimmtrak (tebentafusp-tebn). This drug works by targeting a lineage antigen (gp100) present in melanocytes and melanoma. With the rising investments in research and development of new treatments for rare forms of eye cancers, the drug pipeline for uveal melanoma is poised to lead to the market entry of promising treatment options.
This section of the report covers the analysis of unresectable melanoma drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for uveal melanoma. There are around 26 drugs in phase II for uveal melanoma.
The drug molecule categories covered under uveal melanoma pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The choice of treatment depends on multiple factors including the size and location of the tumor, the patient's health and age, and whether the tumor has spread to other parts of the body.
The EMR report for the uveal melanoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveal melanoma clinical trials:
Major drugs currently in the pipeline are as follows:
This drug is under investigation to treat patients with primary indeterminate lesions or small choroidal melanoma, a type of uveal melanoma. It is in Phase 3 of a randomized, masked, controlled study sponsored by Aura Biosciences.
Melatonin tablet (20 mg) is in a Phase 3 randomized trial, where its efficacy in preventing or delaying the development of metastases in around 100 patients diagnosed with primary uveal melanoma will be tested.
In Phase 2 multi-center open-label study, this drug is being assessed for its treatment efficacy in primary uveal melanoma patients. Sponsored by IDEAYA Biosciences, the trial is estimated to enroll 82 participants.
Currently, in Phase 1 of an open-label study, Lifileucel, a cryopreserved autologous tumor-infiltrating lymphocyte (TIL) therapy, is under investigation for the treatment of patients with metastatic uveal melanoma.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Uveal Melanoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveal melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within uveal melanoma pipeline insights.
Global Intraocular Melanoma Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share